Position in CAI
as of Mar 31, 2026
· filed May 13, 2026
Position Value
$51,565
New position
Shares Held
2,884
first reported quarter
Ownership
0.001%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 0%
Shared 0%
None 100%
Position in Biotechnology
Healthcare · as of Jun 30, 2026QUADRANT CAPITAL GROUP LLC holds $22,827,015 across 21 Biotechnology names.
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
2,887 | $2,678,471 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
4,938 | $2,452,852 | |
| 3 | REGN |
Regeneron Pharmaceuticals, Inc.
|
3,691 | $2,301,486 | |
| 4 | LGND |
Ligand Pharmaceuticals Inc
|
5,658 | $1,788,437 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
49,246 | $1,742,815 | |
| 6 | EXEL |
Exelixis, Inc.
|
30,229 | $1,644,759 | |
| 7 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
2,605 | $1,398,754 | |
| 8 | ONC |
BeOne Medicines Ltd.
|
4,647 | $1,324,255 |
All Filings in CAI
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $51,565 | 2,884 | Shares | Sole | 2026-05-13 | |
| No filing history on record for this holder in this stock. | ||||||